124 related articles for article (PubMed ID: 38846085)
21. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.
Park HJ; Ahn KJ; Ahn SD; Choi E; Lee SW; Williams B; Kim EJ; Griffin R; Bey EA; Bornmann WG; Gao J; Park HJ; Boothman DA; Song CW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):212-9. PubMed ID: 15629614
[TBL] [Abstract][Full Text] [Related]
22. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
23. β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.
Park MT; Song MJ; Lee H; Oh ET; Choi BH; Jeong SY; Choi EK; Park HJ
PLoS One; 2011; 6(10):e25976. PubMed ID: 21998736
[TBL] [Abstract][Full Text] [Related]
24. NQO1 induction mediated by photodynamic therapy synergizes with β-Lapachone-halogenated derivative against melanoma.
Lamberti MJ; Morales Vasconsuelo AB; Chiaramello M; Ferreira VF; Macedo Oliveira M; Baptista Ferreira S; Rivarola VA; Rumie Vittar NB
Biomed Pharmacother; 2018 Dec; 108():1553-1564. PubMed ID: 30372857
[TBL] [Abstract][Full Text] [Related]
25. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
Park HJ; Choi EK; Choi J; Ahn KJ; Kim EJ; Ji IM; Kook YH; Ahn SD; Williams B; Griffin R; Boothman DA; Lee CK; Song CW
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8866-71. PubMed ID: 16361576
[TBL] [Abstract][Full Text] [Related]
26. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
[TBL] [Abstract][Full Text] [Related]
27. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
Bentle MS; Reinicke KE; Dong Y; Bey EA; Boothman DA
Cancer Res; 2007 Jul; 67(14):6936-45. PubMed ID: 17638905
[TBL] [Abstract][Full Text] [Related]
28. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
29. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
[TBL] [Abstract][Full Text] [Related]
30. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
Blanco E; Bey EA; Dong Y; Weinberg BD; Sutton DM; Boothman DA; Gao J
J Control Release; 2007 Oct; 122(3):365-74. PubMed ID: 17574288
[TBL] [Abstract][Full Text] [Related]
31. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
[TBL] [Abstract][Full Text] [Related]
32. Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
Li Y; Feng M; Guo T; Wang Z; Zhao Y
Adv Healthc Mater; 2023 Aug; 12(20):e2300349. PubMed ID: 36970948
[TBL] [Abstract][Full Text] [Related]
33. eIF2 kinases mediate β-lapachone toxicity in yeast and human cancer cells.
Menacho-Márquez M; Rodríguez-Hernández CJ; Villaronga MÁ; Pérez-Valle J; Gadea J; Belandia B; Murguía JR
Cell Cycle; 2015; 14(4):630-40. PubMed ID: 25590579
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial activity is the key to the protective effect of β-Lapachone, a NAD
Lin SY; Syu JP; Lo YT; Chau YP; Don MJ; Shy HT; Lai SM; Kung HN
Phytomedicine; 2022 Jul; 101():154094. PubMed ID: 35447421
[TBL] [Abstract][Full Text] [Related]
35. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB.
Dong GZ; Oh ET; Lee H; Park MT; Song CW; Park HJ
Exp Mol Med; 2010 May; 42(5):327-34. PubMed ID: 20200474
[TBL] [Abstract][Full Text] [Related]
36. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
37. Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilisation of NQO1 protein.
Dong GZ; Youn H; Park MT; Oh ET; Park KH; Song CW; Choi EK; Park HJ
Int J Hyperthermia; 2009; 25(6):477-87. PubMed ID: 19657853
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
[TBL] [Abstract][Full Text] [Related]
39. Following anticancer drug activity in cell lysates with DNA devices.
Kahanda D; Singh N; Boothman DA; Slinker JD
Biosens Bioelectron; 2018 Nov; 119():1-9. PubMed ID: 30098460
[TBL] [Abstract][Full Text] [Related]
40. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1.
Kolossov VL; Ponnuraj N; Beaudoin JN; Leslie MT; Kenis PJ; Gaskins HR
Biochem Biophys Res Commun; 2017 Jan; 483(1):680-686. PubMed ID: 27986568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
